Morgan Stanley Rates Omada Health (OMDA) buy, $30 Price Target

Morgan Stanley reaffirms its buy rating for Omada Health, setting a price target of $30, a 61.29% upside from the current price.

By TradeTexts Research Desk · Published Jun 22, 2026, 2:01 PM EDT · Updated Jun 25, 2026, 2:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Morgan Stanley rated Omada Health, Inc. ($OMDA) "buy" with a $30 price target on June 22, 2026.

Since the rating, $OMDA is up 20.5% after 1 week, up 21.5% after 1 month and down 1.9% to date (from the $17.98 close on Jun 22, 2026).

OMDA Omada Health, Inc.

$17.63 +18.32% year to date

Daily close · Oct 16, 2026

Key Points

Morgan Stanley reiterated its buy rating for Omada Health, Inc. on June 22, 2026, with a price target of $30.
Morgan Stanley's $30 price target implies 61.29% upside from Omada Health, Inc.'s ($OMDA) current $18.60 share price.
Shares of NasdaqGS:OMDA traded near $17.64 on Monday, with the company having a market cap of about $1.05 billion and a forward P/E ratio of 37.02.
Several insiders, including Sachin Jain and Jonathan Root, bought shares on June 16, 2026, with no reported transaction value.

Get $OMDA trade alerts by text

We text you when insiders, Congress or big funds trade $OMDA. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Omada Health, Inc. alert may contain errors. Disclosures

Morgan Stanley has reiterated its buy rating for Omada Health, Inc. (NasdaqGS:OMDA) on June 22, 2026. The firm set a price target of $30, indicating confidence in the company's future prospects. Omada Health's stock traded near $17.64 on Monday, reflecting the latest market sentiment.

Analyst rating track record

Morgan Stanley vs. the S&P 500

YTD return +27.56% hypothetical

All-time return +24.24% S&P 500 +34.72%

vs. S&P 500 -10.48% behind the index

Hypothetical returns from Morgan Stanley's disclosed trades, not real profit or advice. How we model this.

Omada Health, Inc. Stock Down 9.0%

Shares of Omada Health, Inc. were trading around $17.64 as of Monday. The company boasts a market capitalization of approximately $1.05 billion. Despite not being profitable, Omada Health has a forward P/E ratio of 37.02, suggesting growth expectations. The stock has ranged from a low of $10.28 to a high of $26.92 over the past year. Its 50-day moving average is $15.77, while the 200-day moving average is $17.25. Omada Health maintains a robust financial position with a current ratio of 3.92 and a quick ratio of 3.69.

12-month forecast

$OMDA price target

Omada Health, Inc. daily closes and this analyst's $30 target. Not advice.

Recent Earnings

In its recent earnings report, Omada Health recorded revenue of $283.3 million, reflecting a growth rate of 42%. The company remains unprofitable, with an EPS of -$0.23 and a net margin of -2.22%. Its return on equity is -4.30%. Investors are looking forward to the next earnings announcement on August 6, 2026.

Insider Buying and Selling at Omada Health, Inc.

A group of insiders, including Sachin Jain, Jonathan Root, and others, each purchased 10,882 shares of Omada Health on June 16, 2026. These transactions were not planned under Rule 10b5-1 and did not specify a transaction value, indicating potential confidence in the company's future.

Analysts Set New Price Targets

Morgan Stanley reiterated its buy rating for Omada Health on June 22, 2026, with a price target of $30. Other analysts have also shown support, with Barclays, Citizens, and Evercore ISI Group maintaining buy ratings in recent months. The consensus among 12 analysts is a buy rating, with an average target price of $22.92, ranging from a low of $15 to a high of $30.

About Omada Health, Inc.

Omada Health, Inc. is a healthcare company based in South San Francisco, California. It provides virtual care programs focusing on cardiometabolic conditions such as prediabetes, diabetes, and hypertension, as well as physical therapy and weight management. Led by CEO Sean P. Duffy, the company offers its services to employers, health plans, and pharmacy benefits managers.

Bottom Line

Morgan Stanley's reiterated buy rating and $30 price target for Omada Health underscore the firm's confidence in the company's growth potential. With its focus on virtual healthcare solutions, Omada Health continues to attract attention from investors. However, as with all 13F filings and analyst ratings, these insights are backward-looking and do not necessarily reflect the current state of affairs.